

1 *STOP-Bang questionnaire should be used in all adults with Down Syndrome to*
2 *screen for moderate to severe obstructive sleep apnea*

3

4

5

6 Anderson Albuquerque de Carvalho^{1,2*#a¶}, Fábio Ferreira Amorim^{3&}, Levy Aniceto
7 Santana^{3&}, Karlo Josefo Quadros de Almeida^{4&}, Alfredo Nicodemos da Cruz
8 Santana^{2,3¶}, Francisco de Assis Rocha Neves^{1¶}

9

10

11

12 ¹Department of Postgraduate Health Sciences, Universidade de Brasília, Faculdade de
13 Ciências da Saúde, Brasília, Distrito Federal, Brazil.

14 ²Respiratory Department, Multidisciplinary Sleep Unit, Hospital Regional da Asa
15 Norte, Brasília, Distrito Federal, Brazil.

16 ³Department of Postgraduate Health Sciences, Escola Superior de Ciências da Saúde,
17 Faculdade de Medicina e Enfermagem, Brasília, Distrito Federal, Brazil.

18 ⁴Regional Board of Secondary Care Department, Hospital Regional da Asa Norte,
19 Centro de Referência Interdisciplinar em Síndrome de Down, Brasília, Distrito Federal,
20 Brazil.

21

22 ^{#a} Current Address: Respiratory Department, Multidisciplinary Sleep Unit, Hospital
23 Regional da Asa Norte, Brasília, Distrito Federal, Brazil.

24

25 * Corresponding author

26 E-mail: carvalhofisio2003@gmail.com (AAC)

27

28 **Conflicts of Interest**

29 The authors declare that they have viewed and approved the manuscript and that the
30 opinions expressed in the submitted article are theirs and not an official position of the
31 institution or the funder. This study was not supported by the industry. The other
32 authors have no conflicts of interest to declare.

33

34 **Sources of Funding**

35 The study received financial support through process number 064.000.560/2015 of
36 Public Notice number 40 of 10/29/2015, published in DODF n. 213, of 11/06/2015,
37 regarding the Homologation of the Final Selection Result of Research Projects to be
38 funded by *Fundação de Ensino e Pesquisa em Ciências da Saúde* (FEPECS).

39

40

41

42

43

44

45

46

47

48 **Abstract**

49 **Study Objectives**

50 To determine the prevalence of obstructive sleep apnea (OSA) in adults with
51 Down syndrome (DS), to investigate factors related to OSA severity and to identify
52 which sleep questionnaire is the most appropriate for the screening of OSA in this
53 population.

54 **Methods**

55 Cross-sectional study that consecutively included 60 adults with DS. All patients
56 underwent type III polysomnography and clinical and laboratory data were collected;
57 sleep assessment questionnaires were applied. Multiple linear regression models
58 evaluated the associations between OSA severity (measured by the respiratory event
59 index - REI) and clinical and laboratory data and sleep questionnaires (Epworth
60 Sleepiness Scale, Pittsburgh Sleep Quality Index, BERLIN and STOP-Bang
61 questionnaires).

62 **Results**

63 Results show that 60 (100%) adults with DS had OSA, with moderate-severe
64 OSA identified in 49 (81.6%). At the multivariate linear regression, REI significantly
65 correlated with hematocrit levels, BMI and STOP-Bang questionnaire (SBQ) results (P
66 <0.001). The positive STOP-Bang ≥ 3 points) showed 100% of sensitivity (95%CI:
67 92.75-100%), 45.45% of specificity (95%CI: 16.75-76.62), positive predictive value of
68 89.09% (95%CI: 82.64-93.34%), negative predictive value of 100%, accuracy of 90%
69 (95%CI: 79.49-96.24%) and OR of 24.29.

70 **Conclusions**

71 Adults with DS have a very high prevalence of OSA. Hematocrit levels, BMI
72 and SBQ showed a strong correlation with OSA severity. The SBQ performed well in
73 identifying moderate to severe OSA in this population. Considered together, these
74 results point to the need to perform OSA screening in all adults with DS, and STOP-
75 Bang may play a role in this screening.

76 **Keywords**

77 Down syndrome; obstructive sleep apnea; self-reported sleep quality; sensitivity and
78 specificity; surveys and questionnaires; polysomnography.

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96 **Introduction**

97 Down syndrome (DS) is the most prevalent chromosomal abnormality, with
98 approximately 5.4 million affected individuals worldwide[1], with 206,000 of these
99 patients in the United States[2]. In the last decades, the life expectancy of individuals
100 with DS has considerably increased and currently exceeds 60 years in developed
101 countries.[1] A common comorbidity in adults with DS is obstructive sleep apnea
102 (OSA), of which prevalence ranges from 78-100% in these individuals.[3-8] Moreover,
103 when compared to the general population, the OSA is more often classified as severe
104 and is associated with more significant hypoxemia in individuals with DS.[3] In turn,
105 OSA-related hypoxemia has been associated with decreased verbal IQ, executive
106 function, visual-perceptual skills and increase in mood disorders in patients with DS.[9]

107 The higher prevalence and severity of OSA in patients with DS is related to the
108 phenotypic characteristics of DS itself. These changes include upper airway hypotonia,
109 midface hypoplasia, mandibular hypoplasia, glossoptosis, lingual tonsil hypertrophy,
110 pharyngomalacia, laryngomalacia, and tonsil / adenoid hypertrophy. Additionally,
111 factors such as obesity and hypothyroidism, which are also frequently observed in
112 individuals with DS, favor OSA onset.[3,9,10]

113 Despite the high risk for OSA in individuals with DS, recommendations for
114 OSA screening and polysomnography in this population are not well established. The
115 American Academy of Pediatrics recommends that polysomnography be performed in
116 all children with DS up to the age of 4, or earlier, if OSA symptoms are present.[11] As
117 for adult patients with DS, the recommendation is also to perform OSA screening, but it
118 is not clearly defined how the screening should be performed (e.g., using a
119 questionnaire or through polysomnography), nor the periodicity of this screening (e.g.,

120 annual or biannual assessment). Another important issue is that, for the adult population
121 with DS, there are no validated questionnaires for OSA screening and there is no
122 specific recommendation on which questionnaire should be applied to this special group
123 of patients.

124 Considering that in the overall population, adequate OSA treatment helps to
125 reduce the incidence of comorbidities and improve neurocognitive functions[12], the
126 identification of OSA in patients with DS is essential to ensure a better neurological
127 prognosis.

128 Therefore, the aim of the present study was to evaluate OSA prevalence and
129 factors associated with OSA severity in adult patients with DS. Moreover, we
130 investigated which questionnaire is the most appropriate for OSA screening in this
131 population.

132

133 **Methods and materials**

134 This study was carried out from October 2017 to October 2018 and included 66
135 adults with DS attending the Down Syndrome Reference Center (CRISDOWN) of
136 Hospital Regional da Asa Norte (HRAN) linked to Faculdade de Medicina da Escola
137 Superior de Ciências da Saúde (ESCS), Brasília, Federal District, Brazil.

138 Subjects were sequentially recruited and submitted to type III polysomnography,
139 anthropometric data collection, laboratory tests and sleep assessment questionnaires.

140 The inclusion criteria comprised individuals with DS treated at our service, of
141 both genders, good overall health status, aged 18 years and older, capable to understand
142 and accept the study and its procedures. The following were excluded: (1) individuals
143 under 18 years of age; (2) patients undergoing treatment for sleep disorders; (3) patients

144 with a history of conditions that could affect brain structure or function (such as
145 cerebrovascular accident or head trauma); (4) those who refused to participate in the
146 study.

147 A researcher explained the study in details to all participants with DS and their
148 proxies. Those who agreed to participate in the study signed the free and informed
149 written consent form. The study was approved by the Research Ethics Committee of
150 Fundação de Ensino e Pesquisa em Ciências da Saúde (FEPECS) according to Opinion
151 number 1,656,332/2016 and followed the principles established by the Declaration of
152 Helsinki.

153

154 **Data Collection and Research protocol**

155 After the study participants were defined, a structured interview was carried out
156 to collect the following data: age, gender, BMI, neck circumference (NC), Mallampati
157 class and comorbidities. Venous blood samples were obtained for analysis after a
158 fasting period of 12 to 15 hours. Laboratory tests included complete blood count,
159 thyroid stimulating hormone (TSH), fasting glucose, HOMA-IR, alanine
160 aminotransferase (ALT), uric acid, urea, creatinine and sodium levels.

161 The following questionnaires were also applied for sleep assessment: Epworth
162 Sleepiness Scale (ESS)[13,14], Pittsburgh Sleep Quality Index (PSQI)[15], BERLIN
163 Questionnaire (BQ)[16,17], and the STOP-Bang Questionnaire (SBQ)[18,19].

164 In the sleep assessment questionnaires, due to the absence of cutoff points
165 specifically defined for the adult population with DS, the ones defined for the overall
166 population were used, as follows: (1) probable presence of excessive daytime sleepiness
167 in the ESS (total score > 10)[13]; (2) poor sleep quality in the PSQI (total score >5)[15];

168 (3) risk for OSA in the BQ (two or more positive categories)[17]; (4) risk for OSA in
169 the SBQ (3 or more affirmative answers)[18]. These questionnaires were answered by
170 the patients' proxies, in agreement with other studies in individuals with DS.[4,5,20]

171 Moreover, all research subjects underwent type III polysomnography according
172 to international guidelines.[21] This type III polysomnography has been previously used
173 in OSA studies in individuals with DS[22] and in other populations[23,24].

174 In the present study, the equipment used to perform the type III PSG
175 assessments was the ApneaLink Air (ResMed Germany Inc.), which has been
176 previously used in other important studies.[23,24] This equipment allowed monitoring
177 with the use of nasal pressure cannula (for airflow and snore detection), chest
178 piezoelectric strap (for respiratory effort detection) and pulse oximetry (to monitor
179 peripheral arterial oxygen saturation - SpO₂ and heart rate).

180 The total recording time was used as the denominator to calculate the respiratory
181 event index (REI).[21,25] The PSG was assembled by a specialized technician from the
182 Sleep Laboratory of our service. The patient was then referred to a temperature-
183 controlled and quiet bedroom, to undergo the all-night test, without the technician's
184 supervision. All patients were accompanied by a proxy during the examination, who
185 slept in a separate bed, but in the same room. Recording of sleep examination records
186 started at 8pm and stopped at 7am in the following morning.

187 The respiratory events were defined as follows: (1) hypopnea, when there was a
188 $\geq 30\%$ reduction in airflow for at least 10 seconds, observed through the nasal cannula,
189 associated with a decrease in SpO₂ of at least 3%; (2) obstructive apnea, due to the
190 absence or reduction $\geq 90\%$ of airflow for at least 10 seconds in the presence of
191 respiratory effort; (3) mixed apnea, due to the absence or reduction $\geq 90\%$ of airflow,
192 without the presence of respiratory effort only at the beginning of the event; (4) central

193 apnea, due to absence or $\geq 90\%$ reduction in airflow for at least 10 seconds associated
194 with absence of respiratory effort throughout the event.[26]

195 The OSA was then classified as mild, moderate or severe. It was classified as
196 mild OSA when the REI was between 5 and 14.9 events / hour, moderate when the REI
197 was between 15 and 29.9 events / hour and severe when the REI was 30 or more events
198 / hour (detected by type III polysomnography).[26]

199 The polysomnography exams were manually reviewed by a single physician
200 according to AASM standardized criteria.[26] The examiner was blinded to any patient
201 clinical data. The PSG examinations were considered valid when there was ≥ 4 hours of
202 adequate recording without significant loss of sensor signal (nasal pressure cannula,
203 pulse oximetry and chest strap).[27-29]

204

205 **Statistical Analysis**

206 Numerical data are presented as mean and standard deviation. Categorical data
207 are presented as absolute numbers and percentage. The statistical analysis was initially
208 performed with simple (univariate) linear regression analysis to identify factors
209 correlated with REI. Subsequently, variables with p-values <0.15 were considered for
210 the multiple linear regression analysis, using variable selection according to the
211 backward technique. A p-value <0.05 was used as the criterion for the retention of
212 variables in the final multiple linear regression model.[30,31] Logarithmic
213 transformation was used to obtain the dependent variable distribution normalization.
214 Assumptions of normality, homocedascity (constant variance) and residual
215 independence were assessed. The presence of multicollinearity was assessed by

216 estimating the variance inflation factor (VIF), with $VIF > 5$ being used as an indication
217 of multicollinearity in the multiple linear regression analysis.[31]

218 The adjusted coefficient of determination R^2 was used as a measure of fit
219 quality. Normality was assessed by visual inspection of histograms and by applying the
220 Shapiro-Wilk normality test.[32,33]

221 The sleep questionnaires that remained in the final multiple linear regression
222 analysis model were used as categorical variable (positive or negative questionnaire)
223 together with moderate to severe OSA (present or absent) in 2x2 contingency tables.
224 Consequently, odds ratio (OR), sensitivity, specificity, positive predictive value (PPV),
225 negative predictive value (NPV) and accuracy were calculated.

226 The R software (R Foundation, Vienna, Austria) was used for statistical data
227 analysis.[32,33] All hypothesis tests were bilateral. Values of $p < 0.05$ were considered
228 significant.

229

230 **Results**

231 During the study period, 66 adults with DS were included in the research. Of
232 this total, 60 completed and 06 patients (9%) dropped out of the study out of their own
233 will. Ten percent (6 subjects) had to undergo the PSG again due to technical problems,
234 such as loss of signal from one of the sensors.

235 Table 1 shows the participants' demographic characteristics (N = 60). A total
236 of 33 men (55%) and 27 women (45%) participated in the study and the mean age of the
237 sample was 27.7 ± 9.1 years. Obesity and overweight were observed in 27 (45%) and 14
238 (23%) subjects, respectively. Oropharyngeal examination showed that 52 (86%)
239 participants were Mallampati class III or IV. Clinically, 30 individuals (50%) were

240 diagnosed with congenital heart disease, and 7 had undergone previous surgical
241 correction.

242 **TABLE 1. Clinical and laboratory characteristics of adult participants with Down**
243 **syndrome.**

Variable	Overall
Age, years	27.7± 9.1
Gender, Male sex	33 (55%)
BMI, kg/m ²	27.9 ± 5.9
Overweight	14 (23%)
Obesity	27 (45%)
Neck circumference, cm	40 ± 3.7
Mallampati class, 3-4	52 (86%)
Hypothyroidism	40 (66%)
Congenital cardiopathies	30 (50%)
Uric acid	6.2 ±1.5
Creatinine	0.96 ± 0.18
Glucose	63.9 ± 34.4
Hematocrit	47.7 ± 5.4
HOMA-IR	6.3 ± 6.2
Sodium	140.1 ± 2.9
ALT	23.1 ± 10.1
TSH	2.6 ± 1.8
Urea	29.6 ± 11.2

244 Values are shown as mean \pm SD, N (%). SD = standard deviation, BMI = body mass
 245 index, ALT = alanine aminotransferase, TSH = thyroid stimulating hormone. N = 60.

246

247 Regarding the questionnaires used for sleep assessment (Table 2) it was
 248 observed that: (1) ESS suggested sleepiness (ESS >10) in 32 participants (53%); (2)
 249 PSQI identified sleep disorders (PSQI >5) in 37 participants (61%); (3) the BQ and (4)
 250 the SBQ indicated high risk of OSA in 49 participants (81%) and 55 participants (91%),
 251 respectively.

252

TABLE 2. Sleep-related characteristics of adult participants with Down syndrome.

Variable	Overall
REI	30.4 \pm 19
OSA severity	
Mild	11 (18.3%)
Moderate	26 (43.3%)
Severe	23 (38.3%)
(1) ESS score	10.8 \pm 3.9
Total score > 10	32 (53%)
(2) PSQI score	6.4 \pm 2.2
Total score > 5	37 (61%)
(3) BQ score, risk for OSA	49 (81%)
(4) SBQ score, risk for OSA (\geq 3)	55 (91%)

253 Values are shown as mean \pm SD, N (%). SD = standard derivation, REI = respiratory
 254 event index, BMI = body mass index., BQ = Berlin Questionnaire, ESS = Epworth

255 Sleepiness Scale, PSQI = Pittsburgh Sleep Quality Index, SBQ = Stop-Bang
256 Questionnaire. N = 60.

257

258 When performing the type III PSG, it was observed that the 60 (100%) study
259 individuals had OSA ($REI \geq 5$ events / h), with moderate to severe OSA in 49 (81.6%).
260 Central sleep apnea syndrome (> 5 events / h) was not observed in any of the subjects.

261 At the simple linear regression analysis (Table 3), several variables showed a significant
262 linear association with the dependent variable (REI), such as uric acid, glucose,
263 hematocrit, HOMA-IR, BMI, ALT, neck circumference, Mallampati class, BQ, ESS,
264 PSQI and SBQ. However, the multiple linear regression analysis (final model), as
265 shown in Table 4, identified only hematocrit, BMI and SBQ as independent predictors
266 of REI. On average, for every 1-unit increase in the hematocrit or BMI variables, and
267 for SBQ to go from negative to positive, the REI response variable increased by 0.073,
268 0.028, and 0.616 respectively. None of the other sleep questionnaire scores (BQ, ESS,
269 and PSQI) demonstrated a significant positive linear association with REI.

270

TABLE 3. Results of simple (univariate) linear regression analysis for the dependent variable respiratory event index.

Covariate	Level	Regression coefficient (Beta)	95%CI		P-value
			Lower	Upper	
Uric acid		0.230	0.149	0.312	<.001*
Creatinine		0.637	-0.235	1.509	0.149
Glucose		0.024	0.011	0.036	<.001*
Hematocrit		0.082	0.062	0.102	<.001*

HOMA-IR		0.054	0.032	0.075	<.001*
Age		0.014	-0.003	0.031	0.102
BMI		0.034	0.009	0.059	0.01*
Sodium		0.038	-0.015	0.090	0.157
ALT		0.023	0.008	0.037	0.003*
TSH		-0.047	-0.134	0.041	0.288
Urea		0.012	-0.002	0.026	0.083
Congenital cardiopathies	Yes	0.037	-0.278	0.352	0.814
	No	-	-	-	-
BQ score	Positive	0.795	0.446	1.145	<.001*
	Negative	-	-	-	-
ESS score	ESS > 10	0.081	0.046	0.116	<.001*
	-	-	-	-	-
PSQI score	PSQI > 5	0.072	0.005	0.139	0.037*
	-	-	-	-	-
SBQ score	≥3	0.958	0.447	1.469	<.001*
	0-2	-	-	-	-
Neck circumference		0.051	0.010	0.092	0.016*
Mallampati class	3/4	0.837	0.430	1.245	<.001*
	1/2	-	-	-	-
Hypothyroidism	Yes	0.058	-0.276	0.392	0.729
	No	-	-	-	-
Number of drugs	≥ 2	0.312	-0.051	0.675	0.091

used	0/1	-	-	-	-
Gender	Female	-0.227	-0.538	0.084	0.149
	Male	-	-	-	-

BMI = body mass index, ALT = alanine aminotransferase, TSH = thyroid stimulating hormone, BQ = Berlin Questionnaire, ESS = Epworth Sleepiness Scale, PSQI = Pittsburgh Sleep Quality Index, SBQ = Stop-Bang Questionnaire.

*Statistical significance = $p < 0.05$. N = 60 in each of the simple linear regression analyses.

271

Table 4. Results of the multivariate linear regression analysis for the dependent variable respiratory event index.

Covariate	Level	REI			P-value
		Regression coefficient (Beta)	95%CI Lower	95%CI Upper	
Hematocrit		0.073	0.056	0.090	<.001*
BMI		0.028	0.013	0.043	<.001*
SBQ	>=3	0.616	0.289	0.943	<.001*
	0-2	-	-	-	-

272 REI = respiratory event index, BMI = body mass index, SBQ = Stop-Bang
 273 Questionnaire. Adj R-Sq= 0.69. *Statistical significance. N = 60.

274

275 As the SBQ remained in the final multiple linear regression model, the
276 contingency table analysis (2x2) with moderate to severe OSA was performed. Positive
277 SBQ (3 or more affirmative answers) showed 100% of sensitivity (95%CI: 92.75-
278 100%), 45.45% of specificity (95%CI: 16.75-76.62%), 89.09% of PPV (95%CI: 82.64-
279 93.34%), 100% of NPV, 90% of accuracy (95%CI: 79.49-96.24%) and OR of 24.29.
280

281 **Discussion**

282 The present study contributes with important findings. First, when compared to
283 previously published studies[3-8], it included the largest number of adults with DS.
284 Second, it evaluated for the first time the role of the SBQ in OSA screening in this
285 population. Moreover, this was the first study to evaluate the prevalence of OSA in
286 adults with DS in Brazil.

287 Thus, we demonstrated that the prevalence of OSA in individuals with DS in our
288 sample was 100%. Moreover, 81.6% of the subjects had moderate to severe OSA.
289 Interestingly, participants with DS were included in the present study regardless of
290 whether or not they had significant complaints of sleep-disordered breathing. This fact
291 supports the idea of performing active OSA screening in all adult individuals with
292 DS[3,5] during routine consultations. Compared to other OSA studies in adult
293 individuals with DS, the prevalence of OSA was also high and ranged from 78 to 100%.
294 It is noteworthy that the number of individuals included in such studies was usually
295 small, the smallest with 3 patients and the largest with 47 individuals[3-8].

296 The difference in OSA prevalence between studies possibly derives from
297 heterogeneities between them, such as different types of polysomnography for OSA
298 diagnosis, as well as sample characterization and size.

299 Our results also demonstrated that BMI is positively correlated with OSA
300 severity indicated by the REI. This correlation corroborates the high prevalence of the
301 observed moderate to severe OSA, based on the fact that 68% of our adult patients with
302 DS were obese or overweight. This correlation between BMI and REI has been well
303 documented in the overall population[34] and in adults with DS[3,5,6].

304 Interestingly, the hematocrit level is also correlated with OSA severity. This
305 correlation has been previously identified in individuals in the overall population with
306 OSA[35,36]; however, this finding had not yet been demonstrated in the population of
307 adult individuals with DS. This correlation possibly reflects the presence and greater
308 severity of nocturnal hypoxemia that stimulates increased erythropoietin synthesis, with
309 consequent elevated erythrocyte production and increased hematocrit levels[35,36].

310 Regarding the use of questionnaires for OSA screening, our study was the first
311 to identify a questionnaire capable of playing a significant role in OSA screening in
312 adults with DS. The sensitivity and accuracy of the SBQ for detecting moderate to
313 severe OSA was 100% and 90%, respectively.

314 This result indicates that the SBQ should be applied to all adult individuals with
315 DS, thus helping to prioritize individuals who need to undergo the polysomnography.
316 This recommendation becomes important as we observe that the international guidelines
317 indicate OSA screening in adults with DS, but do not clearly indicate how this screening
318 should be performed[37-39].

319 Finally, regarding the results of the BQ, ESS and PSQI questionnaires not
320 showing a role in relation to OSA in our study, that is in accordance with the results of
321 the study by Giménez et al[5].

322 Our study shows some limitations. First, the individuals were submitted to a type
323 III PSG and not to a full PSG test. Consequently, we did not have information related to

324 sleep architecture, and OSA severity (REI) may have been underestimated. However,
325 the type III PSG has been used in DS with good results.[22,40-42] Moreover, the
326 number of technical problems that required the type III PSG to be repeated was small
327 (10% in our study), which is in accordance to previous studies in DS or not (3–
328 18%).[21,22,43-45] The present study was performed in a single center for DS patients
329 from a reference hospital. Therefore, it is possible that our results may represent a
330 specific population of adults with DS, since DS patients treated in a community care
331 institution were not included.

332

333 **Conclusion**

334 In conclusion, our study confirmed the very high prevalence of OSA in adults
335 with DS. Additionally, the SBQ, hematocrit levels and BMI showed a strong correlation
336 with OSA severity. Furthermore, the SBQ showed high sensitivity and specificity in
337 identifying moderate to severe OSA in this population. Taken together, these results
338 indicate the need for OSA screening in all adults with DS. Nevertheless, considering the
339 limited access to polysomnography for all patients, the use of hematocrit levels and
340 BMI, and especially the application of the SBQ can select the individuals at higher risk
341 for OSA who should undergo the polysomnography. However, further studies with a
342 larger population of patients with DS are needed for more definitive conclusions to be
343 drawn.

344

345

346 **Acknowledgement**

347 The authors would like to thank the study participants and their proxies for
348 their patience and contributions to the research.

349

350

351 **References**

- 352 1. Vos T, Allen C, Arora M, Barber RM, Brown A, Carter A, et al. Global, regional,
353 and national incidence, prevalence, and years lived with disability for 310 diseases
354 and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease
355 Study 2015. *Lancet* 2016. doi:10.1016/S0140-6736(16)31678-6.
- 356 2. De Graaf G, Buckley F, Skotko BG. Estimation of the number of people with Down
357 syndrome in the United States. *Genet Med* 2017. doi:10.1038/gim.2016.127.
- 358 3. Trois MS, Capone GT, Lutz JA, Melendres MC, Schwartz AR, Collop NA, et al.
359 Obstructive sleep apnea in adults with Down syndrome. *J Clin Sleep Med* 2009.
- 360 4. Andreou G, Galanopoulou C, Gourgoulianis K, Karapetsas A, Molyvdas P.
361 Cognitive status in Down syndrome individuals with sleep disordered breathing
362 deficits (SDB). *Brain Cogn* 2002. doi:10.1016/S0278-2626(02)00019-2.
- 363 5. Giménez S, Videla L, Romero S, Benejam B, Clos S, Fernández S, et al. Prevalence
364 of sleep disorders in adults with down syndrome: A comparative study of self-
365 reported, actigraphic, and polysomnographic findings. *J Clin Sleep Med* 2018.
366 doi:10.5664/jcsm.7382.
- 367 6. Resta O, Foschino Barbaro M, Giliberti T, Caratozzolo G, Cagnazzo M, Scarpelli F,
368 et al. Sleep related breathing disorders in adults with Down syndrome. *Down Syndr*
369 *Res Pract* 2007. doi:10.3104/reports.138.

- 370 7. Telakivi T, Partinen M, Salmi T, Leinonen L, Härkönen T. Nocturnal periodic
371 breathing in adults with Down's syndrome. *J Intellect Disabil Res* 1987.
372 doi:10.1111/j.1365-2788.1987.tb01340.x.
- 373 8. Clark RW, Schmidt HS, Schuller DE. Sleep-Induced Ventilatory Dysfunction in
374 Down's Syndrome. *Arch Intern Med* 1980.
375 doi:10.1001/archinte.1980.00330130047015.
- 376 9. Lal C, White DR, Joseph JE, Van Bakergem K, LaRosa A. Sleep-disordered
377 breathing in down syndrome. *Chest* 2015. doi:10.1378/chest.14-0266.
- 378 10. Dyken ME, Lin-Dyken DC, Poulton S, Zimmerman MB, Sedars E. Prospective
379 polysomnographic analysis of obstructive sleep apnea in down syndrome. *Arch*
380 *Pediatr Adolesc Med* 2003. doi:10.1001/archpedi.157.7.655.
- 381 11. Bull MJ, Saal HM, Braddock SR, Enns GM, Gruen JR, Perrin JM, et al. Clinical
382 report – Health supervision for children with Down syndrome. *Pediatrics* 2011.
383 doi:10.1542/peds.2011-1605.
- 384 12. Veasey SC, Rosen IM. Obstructive Sleep Apnea in Adults. *N Engl J Med* 2016.
385 doi:10.1056/NEJMcp1816152.
- 386 13. Bertolazi AN, Fagondes SC, Hoff LS, Pedro VD, Barreto SSM, Johns MW.
387 Portuguese-language version of the Epworth sleepiness scale: validation for use in
388 Brazil. *J Bras Pneumol* 2009. doi:10.1590/S1806-37132009000900009.
- 389 14. Johns MW. Daytime sleepiness, snoring, and obstructive sleep apnea; The Epworth
390 Sleepiness Scale. *Chest* 1993. doi:10.1378/chest.103.1.30.
- 391 15. Bertolazi AN, Fagondes SC, Hoff LS, Dartora EG, da Silva Miozzo IC, de Barba
392 MEF, et al. Validation of the Brazilian Portuguese version of the Pittsburgh Sleep
393 Quality Index. *Sleep Med* 2011. doi:10.1016/j.sleep.2010.04.020.

- 394 16. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin
395 Questionnaire to identify patients at risk for the sleep apnea syndrome. *Ann Intern*
396 *Med* 1999. doi:10.7326/0003-4819-131-7-199910050-00002.
- 397 17. Vaz AP, Drummond M, Caetano Mota P, Severo M, Almeida J, Winck JC.
398 Tradução do Questionário de Berlim para língua Portuguesa e sua aplicação na
399 identificação da SAOS numa consulta de patologia respiratória do sono. *Rev Port*
400 *Pneumol* 2011. doi:10.1016/S0873-2159(11)70015-0.
- 401 18. Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, et al.
402 STOP questionnaire: A tool to screen patients for obstructive sleep apnea.
403 *Anesthesiology* 2008. doi:10.1097/ALN.0b013e31816d83e4.
- 404 19. Fonseca LB de M, Silveira EA, Lima NM, Rabahi MF. STOP-Bang questionnaire:
405 translation to Portuguese and cross-cultural adaptation for use in Brazil. *J Bras*
406 *Pneumol* 2016. doi:10.1590/s1806-37562015000000243.
- 407 20. Hill E, Fairley D, Van Putten S, Cooper S, Forbes J, Williams L, et al. Use of the
408 pictorial Epworth Sleepiness Scale in adults with Down's syndrome. *J Sleep Res*
409 2012. doi:<http://dx.doi.org/10.1111/j.1365-2869.2012.01044.x>.
- 410 21. Collop NA, Anderson WMD, Boehlecke B, Claman D, Goldberg R, Gottlieb DJ, et
411 al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of
412 obstructive sleep apnea in adult patients. *J Clin Sleep Med* 2007. Available from:
413 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556918/>
- 414 22. Dudoignon B, Amaddeo A, Frapin A, Thierry B, de Sanctis L, Arroyo JO, et al.
415 Obstructive sleep apnea in Down syndrome: Benefits of surgery and noninvasive
416 respiratory support. *Am J Med Genet Part A* 2017. doi:10.1002/ajmg.a.38283.
- 417 23. Corral J, Sánchez-Quiroga M-Á, Carmona-Bernal C, Sánchez-Armengol Á,
418 Sánchez-de-la-Torre A, Durán-Cantolla J, et al. Conventional Polysomnography is

- 419 Not Necessary for the Management of Most Patients with Suspected Obstructive
420 Sleep Apnea. *Am J Respir Crit Care Med* 2017. doi:10.1164/rccm.201612-2497OC.
- 421 24. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, et al. CPAP for
422 Prevention of Cardiovascular Events in Obstructive Sleep Apnea. *N Engl J Med*
423 2016. doi:10.1056/nejmoa1606599.
- 424 25. Kushida CA, Littner MR, Morgenthaler T, Alessi CA, Bailey D, Coleman J, et al.
425 Practice Parameters for the Indications for Polysomnography and Related
426 Procedures: An Update for 2005. *Sleep* 2005. doi:10.1093/sleep/28.4.499.
- 427 26. Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, et al. Rules for
428 scoring respiratory events in sleep: Update of the 2007 AASM manual for the
429 scoring of sleep and associated events. *J Clin Sleep Med* 2012.
430 doi:10.5664/jcsm.2172.
- 431 27. Erman MK, Stewart D, Einhorn D, Gordon N, Casal E. Validation of the
432 ApneaLink™ for the screening of sleep apnea: A novel and simple single-channel
433 recording device. *J Clin Sleep Med* 2007. Available from:
434 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978315/>
- 435 28. Urschitz MS, Brockmann PE, Schlaud M, Poets CF. Population prevalence of
436 obstructive sleep apnoea in a community of German third graders. *Eur Respir J*
437 2010. doi:10.1183/09031936.00078409.
- 438 29. Brockmann PE, Perez JL, Moya A. Feasibility of unattended home
439 polysomnography in children with sleep-disordered breathing. *Int J Pediatr*
440 *Otorhinolaryngol* 2013. doi:10.1016/j.ijporl.2013.09.011.
- 441 30. Zar, Jerrold H. *Biostatistical Analysis*. 5th Edition. Pearson Prentice-Hall; 2010.
- 442 31. Montgomery, D.C., Peck, EA, and Vining, G.G. *Introduction to Linear Regression*
443 *Analysis*, 5th ed., John Wiley and Sons, Hoboken, NJ; 2012.

- 444 32. Nicholas J. Horton, Ken Kleinman - Using R for Data Management, Statistical
445 Analysis, and Graphics CRC Press, 2011; pp 93–118.
- 446 33. The R Project for Statistical Computing. Available from: <https://www.r-project.org>
- 447 34. Durán J, Esnaola S, Rubio R, Iztueta Á. Obstructive sleep apnea-hypopnea and
448 related clinical features in a population-based sample of subjects aged 30 to 70 yr.
449 Am J Respir Crit Care Med 2001. doi:10.1164/ajrccm.163.3.2005065.
- 450 35. Choi JB, Loredó JS, Norman D, Mills PJ, Ancoli-Israel S, Ziegler MG, et al. Does
451 obstructive sleep apnea increase hematocrit? Sleep Breath 2006.
452 doi:10.1007/s11325-006-0064-z.
- 453 36. Wu M, Zhou L, Zhu D, Lai T, Chen Z, Shen H. Hematological indices as simple,
454 inexpensive and practical severity markers of obstructive sleep apnea syndrome: A
455 meta-analysis. J Thorac Dis 2018. doi:10.21037/jtd.2018.10.105.
- 456 37. Van Allen MI, Fung J, Jurenka SB. Health care concerns and guidelines for adults
457 with Down syndrome. Am J Med Genet - Semin Med Genet 1999.
458 doi:10.1002/(SICI)1096-8628(19990625)89:2<100::AIDAJMG8>3.0.CO;2-N.
- 459 38. Ivan DL, Cromwell P. Clinical practice guidelines for management of children with
460 down syndrome: Part II. J Pediatr Heal Care 2014.
461 doi:10.1016/j.pedhc.2013.05.003.
- 462 39. Smith DS, Meurer LN, Bower D. Health Care Management of Adults with Down
463 Syndrome PRACTICAL THERAPEUTICS Selected Medical Conditions with a
464 Higher Prevalence in Adults with Down Syndrome*. 2001. Available:
465 [chromeextension://oemmndcbldboiebfnladdacbfmadadm/https://pdfs.semanticscho](chromeextension://oemmndcbldboiebfnladdacbfmadadm/https://pdfs.semanticscholar.org/7ba7/4d3de5a3d02673666139b259323a0550990e.pdf)
466 <lar.org/7ba7/4d3de5a3d02673666139b259323a0550990e.pdf>
- 467 40. Cohen WI. Health Care Guidelines for Individuals with Down Syndrome-1999
468 Revision. Down Syndr., 2003. doi:10.1002/0471227579.ch17.

- 469 41. De Miguel-Díez J, Villa-Asensi JR, Álvarez-Sala JL. Prevalence of sleep-disordered
470 breathing in children with down syndrome: Polygraphic findings in 108 children.
471 Sleep 2003. doi:10.1093/sleep/26.8.1006.
- 472 42. Hill CM, Evans HJ, Elphick H, Farquhar M, Pickering RM, Kingshott R, et al.
473 Prevalence and predictors of obstructive sleep apnoea in young children with Down
474 syndrome. Sleep Med 2016. doi:10.1016/j.sleep.2016.10.001.
- 475 43. Brockmann PE, Damiani F, Nuñez F, Moya A, Pincheira E, Paul MA, et al. Sleep-
476 disordered breathing in children with Down syndrome: Usefulness of home
477 polysomnography. Int J Pediatr Otorhinolaryngol 2016.
478 doi:10.1016/j.ijporl.2016.01.030.
- 479 44. Alonso-Álvarez ML, Terán-Santos J, Ordax Carbajo E, Cordero-Guevara JA,
480 Navazo-Egüia AI, Kheirandish-Gozal L, et al. Reliability of home respiratory
481 polygraphy for the diagnosis of sleep apnea in children. Chest 2015.
482 doi:10.1378/chest.14-1959.
- 483 45. De Jesus Danzi-Soares N, Genta PR, Nerbass FB, Pedrosa RP, Soares FSN, César
484 LAMH, et al. Obstructive sleep apnea is common among patients referred for
485 coronary artery bypass grafting and can be diagnosed by portable monitoring. Coron
486 Artery Dis 2012. doi:10.1097/MCA.0b013e32834df5d0.